- The serology test has a specificity greater than 99.8% and sensitivity of 100% (14 Days post-PCR confirmation)
- The high specificity of the test is crucial to determine reliably if a person has been exposed to the virus and if the patient has developed antibodies
- Roche will provide high double-digit millions of tests already in May for countries accepting the CE mark and in the U.S. under Emergency Use Authorization, further ramping up capacities thereafter
- The test is available on Roche’s cobas e analysers which are widely available around the world
Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
No Comments
Previous Post
Support to health workers on COVID-19 through a WHO App
Next Post
Roche begins trial of Actemra/RoActemra plus remdesivir
Recent Posts
- Gilead’s cell therapy Yescarta awarded FDA approval for follicular lymphoma 08/03/2021
- FDA approval brings remote programming for Abbott’s deep brain stimulation device 08/03/2021
- Beckman Coulter seeks authorization for $4 antigen test 28/01/2021
- 3 tech-driven innovative patient engagement strategies transforming healthcare today 09/12/2020
- Lucira Covid-19 test is first to get FDA nod for home use 19/11/2020
Categories
- Coding (3)
- news (17)
- Photography (3)
- Social Marketing (3)
- uncategorized (1)
- WordPress (4)